Oncology

Recent data link a higher consumption of ultraprocessed food to increased lung cancer risk, highlighting the need for dietary changes and further research.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.

PHESGO reduced patient infusion time from 90 minutes to as few as 5, enhancing patient experience while maintaining efficacy and safety.

August marks a pivotal time for oncology pharmacy, blending transitions, celebrations, and new beginnings as professionals prepare for the upcoming season.

Herzuma shows promising efficacy and safety as a cost-effective biosimilar for treating HER2+ advanced gastric cancer, offering new hope for patients.

Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.

AI is transforming oncology by enhancing clinical trials, personalizing treatments, and improving pharmacy practices, promising faster, more precise cancer care.

Lawmakers across the country can learn from examples in states like Arkansas and Texas.

Pirtobrutinib shows promising results in a head-to-head trial against ibrutinib for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

Hormonal contraceptives present a nuanced risk-benefit profile, slightly increasing breast and cervical cancer risk while significantly reducing ovarian and endometrial cancer rates.

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.

Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

George Wang discusses the widespread financial barriers patients with cancer face, the environmental and economic toll of oncology drug waste, and how pharmacist-supported medication donation programs can safely and legally redistribute surplus cancer treatments to patients in need.

The combination regimen had stronger benefits in patients with locally advanced or metastatic epidermal growth receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC) than osimertinib alone.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

Targeting BRD4 with BET inhibitors shows promise in reversing immune suppression by myeloid-derived suppressor cells in chronic lymphocytic leukemia.

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Artificial intelligence (AI) is rapidly transforming oncology by enhancing clinical trial design, streamlining patient recruitment, improving precision medicine, and optimizing pharmacy operations, while raising important challenges around data ethics, bias, and integration into clinical workflows.

Carrie Harney, JD, of US Pharmacopeia (USP) discusses how proposed tariffs could impact generic drug supply chains, sterile injectable shortages, and pharmacy operations, underscoring the need for policy incentives and manufacturing diversification.

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

The complete response letter (CRL) did not raise safety concerns, but stated the IGNYTE trial was inadequate and did not provide substantial evidence of effectiveness.

With AI-enhanced pharmacogenetics, pharmacists lead the shift to truly individualized medicine.

Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.

Neladalkib enters phase 3 trials, targeting advanced ALK-positive NSCLC, promising improved outcomes for TKI-naive patients with brain metastases.